JP5210630B2 - 撮像におけるコントラストを強調するための組成物および方法 - Google Patents

撮像におけるコントラストを強調するための組成物および方法 Download PDF

Info

Publication number
JP5210630B2
JP5210630B2 JP2007509455A JP2007509455A JP5210630B2 JP 5210630 B2 JP5210630 B2 JP 5210630B2 JP 2007509455 A JP2007509455 A JP 2007509455A JP 2007509455 A JP2007509455 A JP 2007509455A JP 5210630 B2 JP5210630 B2 JP 5210630B2
Authority
JP
Japan
Prior art keywords
glycero
liposome
liposomes
enhancing agent
contrast enhancing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007509455A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007533737A5 (https=
JP2007533737A (ja
Inventor
アナプラガダ、アナス
ヴィ． ベラムコンダ、ラヴィ
ホフマン、エリック
ヴィジャヤラクシュミ、チャンドラ
ユー カオ、チェン
ガガダ、ケタン
Original Assignee
マーバル バイオサイエンシーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マーバル バイオサイエンシーズ インコーポレイテッド filed Critical マーバル バイオサイエンシーズ インコーポレイテッド
Publication of JP2007533737A publication Critical patent/JP2007533737A/ja
Publication of JP2007533737A5 publication Critical patent/JP2007533737A5/ja
Application granted granted Critical
Publication of JP5210630B2 publication Critical patent/JP5210630B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A61K49/0093—Nanoparticle, nanocapsule, nanobubble, nanosphere, nanobead, i.e. having a size or diameter smaller than 1 micrometer, e.g. polymeric nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2007509455A 2004-04-21 2005-01-12 撮像におけるコントラストを強調するための組成物および方法 Expired - Fee Related JP5210630B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/830,190 US7713517B2 (en) 2004-04-21 2004-04-21 Compositions and methods for enhancing contrast in imaging
US10/830,190 2004-04-21
PCT/US2005/000876 WO2005107820A1 (en) 2004-04-21 2005-01-12 Compositions and methods for enhancing contrast in imaging

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012248028A Division JP2013049702A (ja) 2004-04-21 2012-11-12 撮像におけるコントラストを強調するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2007533737A JP2007533737A (ja) 2007-11-22
JP2007533737A5 JP2007533737A5 (https=) 2008-02-14
JP5210630B2 true JP5210630B2 (ja) 2013-06-12

Family

ID=35136670

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007509455A Expired - Fee Related JP5210630B2 (ja) 2004-04-21 2005-01-12 撮像におけるコントラストを強調するための組成物および方法
JP2012248028A Pending JP2013049702A (ja) 2004-04-21 2012-11-12 撮像におけるコントラストを強調するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012248028A Pending JP2013049702A (ja) 2004-04-21 2012-11-12 撮像におけるコントラストを強調するための組成物および方法

Country Status (7)

Country Link
US (4) US7713517B2 (https=)
EP (2) EP1742669B1 (https=)
JP (2) JP5210630B2 (https=)
CN (1) CN101123996B (https=)
AU (1) AU2005239980B2 (https=)
CA (1) CA2563692C (https=)
WO (1) WO2005107820A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713517B2 (en) * 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
JP5072275B2 (ja) * 2006-07-03 2012-11-14 テルモ株式会社 閉鎖小胞の分離方法、製剤の製造方法および評価方法
CA2600220C (en) * 2006-09-07 2014-12-09 Canadian Blood Services Surface cross-linked lipidic particles, methods of production and uses therefor
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US20110177156A1 (en) * 2007-11-14 2011-07-21 Szoka Jr Francis C Sterol-Modified Amphiphilic Lipids
US8642013B2 (en) * 2007-12-05 2014-02-04 Ananth Annapragada Nano-scale contrast agents and methods of use
US8956591B2 (en) 2008-05-15 2015-02-17 Osaka Prefectural Hospital Organization Method for detecting cancer using ICG fluorescence method
AU2009257279A1 (en) * 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
CN102438591A (zh) * 2009-03-19 2012-05-02 马维尔生物科学公司 用于增强成像对比度的组合物和方法
BR112012033776A2 (pt) * 2010-07-12 2016-11-01 Ge Healthcare As composição,e, método de exame de raios-x.
US8658614B2 (en) 2010-08-13 2014-02-25 The University of Texas Health Science Center Aptamer-containing compositions and methods for targeting E-selectin
WO2012139080A2 (en) * 2011-04-06 2012-10-11 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
WO2012136813A2 (en) 2011-04-07 2012-10-11 Universitetet I Oslo Agents for medical radar diagnosis
CN107982550A (zh) * 2012-01-11 2018-05-04 通用电气医疗集团股份有限公司 具有低碘浓度的x-射线成像造影介质和x-射线成像方法
CA2848994A1 (en) 2012-01-20 2013-07-25 Ananth Annapragada Methods and compositions for objectively characterizing medical images
WO2014047116A1 (en) * 2012-09-18 2014-03-27 Comfort Care For Animals Llc Encapsulating liposomes
EP3047271B1 (en) * 2013-09-20 2022-05-11 California Institute Of Technology Methods for phenotyping of intact whole tissues
EP3204051B1 (en) 2014-10-08 2019-05-29 Texas Children's Hospital Mri imaging of amyloid plaque using liposomes
CN109513017B (zh) * 2018-12-27 2021-09-21 中国科学院高能物理研究所 一种脂质纳米囊及其制备方法和应用
EP3753549A1 (en) 2019-06-20 2020-12-23 InnoMedica Holding AG Liposomal doxorubicin formulation, method for producing a liposomal doxorubicin formulation and use of a liposomal doxorubicin formulation as a medicament
CN115279424A (zh) 2020-02-12 2022-11-01 德克萨斯儿童医院 用于α-突触核蛋白沉积MRI的靶向对比剂
CN115957351B (zh) * 2022-11-15 2023-06-27 中国人民解放军海军第九七一医院 一种碘海醇注射液及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5204085A (en) * 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
CH672733A5 (https=) * 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
DE68901733T2 (de) * 1988-03-04 1993-03-25 Takeda Chemical Industries Ltd Liposom-zusammensetzung.
US4994213A (en) 1988-05-17 1991-02-19 Liposome Technology, Inc. Method of preparing lipid structures
ATE108651T1 (de) * 1988-05-20 1994-08-15 Liposome Co Inc Aktives mittel: lipid-komplex mit hohem verhältnis.
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5230882A (en) * 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
IN172208B (https=) * 1990-04-02 1993-05-01 Sint Sa
GB9314499D0 (en) * 1993-07-12 1993-08-25 Nycomed Imaging As Method
US6217849B1 (en) * 1993-09-29 2001-04-17 Bracco Research S.A. Liposome suspensions as blood pool imaging contrast agents
DE4341472A1 (de) * 1993-12-02 1995-06-08 Schering Ag Verfahren zur Erhöhung der Stabilität von hydrophile Wirkstoffe enthaltenden Liposomensuspensionen
DE69527194T2 (de) * 1994-03-28 2003-02-06 Daiichi Pharmaceutical Co., Ltd. Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
JP3759765B2 (ja) * 1994-03-28 2006-03-29 第一製薬株式会社 リポソーム
US5811581A (en) * 1994-08-04 1998-09-22 Dibra S.P.A. Process for the purification of opacifying contrast agents
US6033645A (en) * 1996-06-19 2000-03-07 Unger; Evan C. Methods for diagnostic imaging by regulating the administration rate of a contrast agent
NZ334365A (en) 1996-08-02 1999-10-28 Nycomed Imaging As Use of a contrast agent comprising microbubbles of biocompatible gas stabilised by opsonisable amphiphilic material for ultrasound imaging of the liver
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
AU7104598A (en) * 1997-04-09 1998-10-30 Philipp Lang New technique to monitor drug delivery noninvasively (in vivo)
WO1998046275A2 (en) * 1997-04-11 1998-10-22 The Board Of Regents Of The University Of Michigan Blood-pool carrier for lipophilic imaging agents
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
KR100679906B1 (ko) 1998-09-16 2007-02-07 알자 코포레이션 리포솜-엔트랩된 토포이소머라제 억제제
US6203778B1 (en) * 1998-12-08 2001-03-20 The Regents Of The University Of California Particulate radiopaque contrast agent for diagnostic imaging and microvascular characterization
US6425864B1 (en) 1999-04-15 2002-07-30 General Electric Company Method and apparatus for optimal imaging of the peripheral vasculature
JP2004510830A (ja) * 2000-10-11 2004-04-08 ターゲサム・インコーポレーテッド 標的化された治療用薬剤
JP2005518266A (ja) 2001-09-28 2005-06-23 エスペリオン セラピューティクス，インコーポレイテッド 高圧でベシクルを押し出す方法および装置
JP2005519129A (ja) * 2002-03-05 2005-06-30 クリーブランド ステート ユニバーシティー エアロゾル薬物送達のための凝集粒子
US20060235296A1 (en) 2003-02-13 2006-10-19 Bracco Imaging S.P.A. Contrast enhanced x-ray phase imaging
JP2005170923A (ja) 2003-10-21 2005-06-30 Konica Minolta Medical & Graphic Inc リポソーム含有ｘ線造影剤およびその製造方法
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
US8357351B2 (en) * 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
WO2006084382A1 (en) 2005-02-11 2006-08-17 University Health Network Compositions and methods for multimodal imaging
US20080213350A1 (en) 2007-02-20 2008-09-04 Texas Tech University System Encapsulation of nucleic acids in liposomes
US8642013B2 (en) * 2007-12-05 2014-02-04 Ananth Annapragada Nano-scale contrast agents and methods of use
AU2009257279A1 (en) * 2008-06-13 2009-12-17 Marval Biosciences, Inc. Imaging of atherosclerotic plaques using liposomal imaging agents
CN102438591A (zh) * 2009-03-19 2012-05-02 马维尔生物科学公司 用于增强成像对比度的组合物和方法

Also Published As

Publication number Publication date
JP2013049702A (ja) 2013-03-14
EP1742669B1 (en) 2015-07-08
CA2563692C (en) 2013-05-14
AU2005239980A1 (en) 2005-11-17
US20080131369A1 (en) 2008-06-05
USRE45195E1 (en) 2014-10-14
HK1117407A1 (en) 2009-01-16
US7713517B2 (en) 2010-05-11
US20070212303A1 (en) 2007-09-13
EP1742669A4 (en) 2010-06-23
US20050238584A1 (en) 2005-10-27
EP2578237A1 (en) 2013-04-10
CN101123996A (zh) 2008-02-13
EP1742669A1 (en) 2007-01-17
CN101123996B (zh) 2014-07-16
AU2005239980B2 (en) 2010-02-25
JP2007533737A (ja) 2007-11-22
CA2563692A1 (en) 2005-11-17
US7785568B2 (en) 2010-08-31
WO2005107820A1 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
JP5210630B2 (ja) 撮像におけるコントラストを強調するための組成物および方法
Kao et al. Long-residence-time nano-scale liposomal iohexol for X-ray–based blood pool imaging
US20120003159A1 (en) Compositions and methods for enhancing contrast in imaging
US8642013B2 (en) Nano-scale contrast agents and methods of use
US8911708B2 (en) Nano-scale contrast agents and methods of use
EP3003396B1 (en) Multimodal ct/optical agents
HK1117407B (en) Compositions and methods for enhancing contrast in imaging
JP4654590B2 (ja) Ｘ線ｃｔ用造影組成物およびその製造方法
JP2005225822A (ja) リポソーム含有ｘ線造影剤
JP2005179214A (ja) Ｘ線検査用造影剤
JP2005170928A (ja) リポソーム含有ｘ線造影剤およびその製造方法
JP2005225791A (ja) リポソーム含有ｘ線検査用造影剤
JP2005145845A (ja) Ｘ線検査用造影剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071217

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A072

Effective date: 20080422

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110131

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110207

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110301

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110329

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110426

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20110513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111116

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20111220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120222

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121207

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20121219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130225

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20160301

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees